Renal cell carcinoma, metastatic

Proleukin Aldesleukin (interleukin 2) Chiron Renal cell carcinoma, metastatic melanoma... [Pg.694]

H. Other considerations Interferon alfa-2a has been designated an orphan drug product for the treatment of chronic myelogenous leukemia, AIDS-related Kaposi s sarcoma, renal cell carcinoma, metastatic malignant melanoma, and esophageal and colorectal cancer. [Pg.192]

H. Other considerations Proleukin has been designated an orphan drug for use in the treatment of metastatic renal cell carcinoma, metastatic melanoma, non-Hodgkin s lymphoma, and primary immunodeficiency disease associated with T-cell defects. [Pg.201]

Aldesleukin (IL-2) Proleukin (Chiron/Novartis) Metastatic renal cell carcinoma metastatic melanoma... [Pg.272]

Aldesleukin interleukin-2 (Proleukin) 15.3 1.42 Intermittent IV infusion (1.0) Metastatic renal cell carcinoma, metastatic melanoma Q i Q O O 7 3 2-... [Pg.346]

Other malignancies Metastatic renal cell carcinoma ... [Pg.644]

Metastatic renal cell carcinoma has a poor prognosis and resists conventional chemotherapy. Immunotherapy with IL-2 and/or IFN-a is currently regarded as the most effective therapy with, however, modest response rates of 15-20%. Similar results are also observed in patients with metastatic melanoma and the response to IFN-a and IL-2 correlates with the occurrence of tumor-infiltrating CD4+ T-lymphocytes identified in aspirates from melanoma metastases. Determination of these cells therefore seems to be a method to predict responders prior to the initiation of cytokine therapy. [Pg.645]

S orafenib (Nexavar ) Bayer TKI VEGFR, PDGFR, KIT, FTL-3, RAF Unresectable or metastatic renal cell carcinoma... [Pg.1193]

Brouwers, A.H., Buijs, W.C.A.M., Oosterwijk, E., Boerman, O.C., Mala, C., De Mulder, P.H.M., Cortens, F.H.M., and Mulders, P.F.A. (2003) Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with 131-1 or 111-In An intrapatient comparison. Clin. Cancer Res. 9(Suppl.), 3953s-3960s. [Pg.1051]

Thompson, J.A. et al., Prolonged continuous intravenous infusion interleukin-2 and lym-phokine-activated killer-cell therapy for metastatic renal cell carcinoma., J. Clin. Oncol., 10, 960, 1992. [Pg.167]

Ratain, M., Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase 11 randomized discontinuation trial (RDT), Proc. Am. Soc. Clin. Oncol., 22, 381, Abstr. 4501, 2004. [Pg.458]

USP received a medication error report involving the products Neumega (oprel-vekin) and Proleukin (aldesleukin). Oprelvekin, a recombinant human interleukin-11 product used to stimulate platelet production in selected patients undergoing chemotherapy, is sometimes abbreviated as IL-11. Aldesleukin, a recombinant human interleukin-2 derivative indicated in designated patient populations for the treatment of metastatic renal-cell carcinoma, is sometimes abbreviated as IL-2. [Pg.160]

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007 356(2) 115-24. [Pg.463]

Bukowski, R.M., Natural history and therapy of metastatic renal cell carcinoma the role of interleukin-2. Cancer, 1997. 80(7) 1198-220. [Pg.177]

Kirkwood, J.M., J.E. Harris, R. Vera, S. Sandler, D.S. Fischer, J. Khandekar, M.S. Ernstoff, L. Gordon, R. Lutes, P. Bonomi, et al., A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma the American Cancer Society collaborative trial Cancer Res, 1985. 45(2) 863-71. [Pg.177]

Quesada, J.R., L. Evans, S.R. Saks, and J.U. Gutterman, Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma. J Biol Response Mod, 1988. 7(3) 234-9. [Pg.177]

G. Other applications Roferon-A has also been used in renal cell carcinoma, multiple myeloma, metastatic melanoma, and primary resected cutaneous melanoma. [Pg.191]

Indications Treatment of adults with metastatic renal cell carcinoma and adults with metastatic melanoma... [Pg.199]

B. Indications and nse Proleukin is indicated for the treatment of adults with metastatic renal cell carcinoma. Proleukin is also indicated for the treatment of adults with metastatic melanoma. Careful patient selection is mandatory prior to the administration of the cytokine. [Pg.200]

Recommended dosage and monitoring requirements The dose of Proleukin in metastatic renal cell carcinoma is 600,000 units/kg every 8 hours for a maximum of 14 doses. Following 9 days of rest, the schedule is repeated for another 14... [Pg.200]

E. Therapeutic response In renal cell carcinoma studies, an objective response was seen in 15% of patients, with 7% complete and 8% partial responders. In metastatic melanoma studies, an objective response was seen in 16% of patients, with 6% complete and 10% partial responders. In patients with HIV infection, Proleukin increases the CD4 count, with no effect on viral load. [Pg.201]

Cottrell, S., Oliver, K., Lake, B.G. Powell, C.J. (1996) Strain-specific enhancement or inhibition of coumarin hepatotoxicity in mice following pretreatment with two different liver enzyme-inducing agents. Fundam. appl. Toxicol, 34, 47-55 Cox, D., O Kennedy, R. Thornes, R.D. (1989) The rarity of liver toxicity inpatients treated with coumarin (1,2-benzopyrone). Hum. exp. Toxicol, 8, 501-506 Dexeus, E.H., Logothetis, C.J., Sella, A., Fitz, K., Amato, R., Reuben, J.M. Dozier, N. (1990) Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma. J. din. Oncol, 8, 325-329... [Pg.218]

Huland, E., Huland, H., and Heinzer, H. (1992). Interleukin-2 by inhalation Local therapy for metastatic renal cell carcinoma. J. Urology, 147, 344—348. [Pg.279]

Reeves, D. J., Liu, C. Y. (2009) Treatment of metastatic renal cell carcinoma. Cancer Chemother Pharmacol 64, 11-15. [Pg.291]

Proleukin is a recombinant human IL-2 that received approval for the treatment of renal cell carcinoma in 1992 and for the treatment of metastatic melanoma in 1998. It is also being evaluated for the treatment of non-Hodgkin s lymphoma (NHL). The therapy is restricted to patients with normal cardiac and pulmonary functions. [Pg.36]

Life-threatening hypothyroidism associated with ciclosporin was reported in a patient treated with reduced-intensity hemopoietic stem cell transplantation for metastatic renal-cell carcinoma (50). [Pg.592]

Patients with metastatic renal cell carcinoma commonly develop mild biochemical thyroid function test abnormalities while taking sorafenib. However, compared with sunitinib, which is associated with a high incidence of thyroid dysfunction, making routine monitoring necessary, patients taking sorafenib need thyroid function monitoring only if clinically indicated (1074). [Pg.648]

Imataki O, Kim SW, Kojima R, Hori A, Hamaki T, Sakiyama M, Murashige N, Satoh M, Kami M, Makimoto A, Takaue Y. Life-threatening hypothyroidism associated with administration of cyclosporine in a patient treated with reduced-intensity hematopoietic stem-cell transplantation for metastatic renal-cell carcinoma. Transplantation 2003 75 898-907. [Pg.659]

Tamaskar IR, Unnithan J, Garcia JA, Dreicer R, Wood L, Iochimescu A, Bukowski R, Rini B. Thyroid function test (TFT) abnormalities in patients (pts) with metastatic renal cell carcinoma (RCC) treated with sorafenib. ASCO Annual Meeting Proceedings. J Clin Oncol 2007 25 (June 20 Suppl) 5048. [Pg.688]

Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007 99 81-3. [Pg.688]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...